Dewpoint Therapeutics launches with $60m Series A to advance proprietary platform for drugging condensates
Founding investor Polaris Partners led the equity round and was joined by Samsara BioCapital, 6 Dimensions Capital, EcoR1 Capital, Alexandria Venture Investments, and Leaps by Bayer. Dewpoint is